US-based digital health firm physIQ has unveiled a new biomarker called eVO2Max to estimate maximum oxygen utilisation (VO2Max) using wearable biosensors and deep neural network technology.
EVO2Max can be produced using 24 hours of nonstop monitoring of vital signs and activity data during daily routine activities.
According to physIQ, the biomarker permits remote assessment at a higher frequency compared to in-clinic testing of cardiopulmonary functional capacity (CFC), such as the cardiopulmonary exercise test (CPET) and the surrogate six-minute walk test (6MWT).
The digital health firm said that the precise assessment of CFC offers vital information into the efficacy of medicines intended to preserve or improve cardiopulmonary function and patients’ quality of life during pharmacological trials.
By giving visibility into patient status and spotting early indicators of decompensation, it has the potential to advance remote monitoring and care of patients with chronic cardiopulmonary disease in medical practice, the health firm claimed http://webbanki.ru/zaim-na-kartu .
As per the company, eVO2Max was created to address the demand for precise and objective functional testing in an ageing population amid an increase in cardiopulmonary disorders. It can be performed in the patient’s regular environment and doesn’t need any particular activity protocol.
The US-based digital health firm said that patients can simply wear a small biosensor for several days and the wirelessly sent data is used by it to estimate a daily VO2Max estimate for remote monitoring by clinicians.
PhysIQ chief digital health officer Matt Pipke said: “Digital biomarkers from wearable sensors show great promise for serving up huge amounts of rich data to better understand how patients are doing in their real world lives.
“eVO2Max is an example of how rich data can update our health measurement toolset from data-sparse practices like the six-minute walk test to continuous, intelligent and easy-to-use evaluations with higher accuracy.”
PhysIQ said that eVO2Max has demonstrated an extremely high correlation to CPET-measured VO2Max across a broad variety of health statuses and age strata, including patients whose health is compromised.
